BRIEF-Xenon Showcases New Long-Term Azetukalner Data From X-Tole Ole Study In Fos At Aes 2024

Reuters
07 Dec 2024

Dec 6 (Reuters) - Xenon Pharmaceuticals Inc :

* XENON SHOWCASES NEW LONG-TERM AZETUKALNER DATA FROM X-TOLE OLE STUDY IN FOS AT AES 2024

* XENON PHARMACEUTICALS INC - OLE DATA SHOWS SUSTAINED MONTHLY REDUCTION IN SEIZURE FREQUENCY, CONSISTENT AE SAFETY PROFILE

* XENON PHARMACEUTICALS INC - ABOUT ONE IN THREE PATIENTS ON DRUG FOR AT LEAST 36 MONTHS ACHIEVED SEIZURE FREEDOM FOR A PERIOD OF ONE YEAR OR LONGER

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10